Celcuity Inc. filings document formal disclosures for a clinical-stage biotechnology company developing targeted oncology therapies. Recent 8-K reports cover gedatolisib and VIKTORIA-1 clinical-trial results in HR+/HER2- advanced breast cancer, FDA-related regulatory updates, financial results, Regulation FD materials, and amendments to a loan and security agreement.
Proxy materials describe annual meeting matters, director elections, auditor ratification, executive compensation votes, stock incentive plans, and employee stock purchase plan amendments. Governance filings also record board composition changes and director compensation arrangements.
Celcuity Inc. (CELC) is the issuer whose common stock Bank of America Corp. reports beneficially owning 1,805,688 shares, or 3.7% of the class. Bank of America reports shared voting power over 1,774,957 shares and shared dispositive power over 1,775,291 shares, with no sole voting or dispositive power. The percentage calculation uses 49,122,601 shares outstanding as of September 30, 2026.
Bank of America Corp. filed on behalf of itself and its wholly owned subsidiaries, including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co. of Delaware. The statement says U.S. Trust's holding does not exceed 1% of the reported securities.
Avoro Capital Advisors LLC and Behzad Aghazadeh each reported beneficial ownership of 1,500,000 shares of Celcuity Inc. (CELC) common stock, representing 3.07% of the class as of September 30, 2026. Both reported sole voting and dispositive power over 1,500,000 shares.
Avoro said it acquired the shares for investment purposes on behalf of Avoro Life Sciences Fund LLC. Aghazadeh serves as Avoro’s portfolio manager and controlling person. The reported percentage was calculated using 48,931,908 shares outstanding as of August 6, 2026.
Celcuity Inc. reported a third-quarter net loss of $73.337 million, compared with $43.804 million a year earlier; nine-month net loss was $205.042 million versus $126.069 million. Third-quarter research and development expense was $37.519 million, and selling, general and administrative expense was $39.800 million.
The FDA approved REVTORPYK on July 14, 2026, and shipments began September 30. No product revenue was recognized for the quarter because healthcare providers and pharmacies had not received product by quarter-end. As of September 30, cash, cash equivalents and short-term investments totaled $642.7 million; management said these funds would cover planned operations for at least one year from issuance of the financial statements.
In June, Celcuity issued $575.0 million aggregate principal amount of 2032 convertible notes, generating $557.0 million in net proceeds. The company used $137.4 million of those proceeds to repay all obligations under its prior loan agreement. Nine-month cash used in operating activities was $176.717 million, compared with $116.881 million a year earlier.
Celcuity Inc. reported a $73.3 million third-quarter net loss, compared with $43.8 million a year earlier, as it launched REVTORPYK, its FDA-approved treatment for HR+/HER2- advanced breast cancer without a detected PIK3CA mutation. Commercial availability began September 30, 2026; 91% of U.S. commercial and Medicare lives are in plans covering the drug, and 78% of the top 36 strategic accounts have ordered it. No product revenue was recognized in the quarter because deliveries to providers or pharmacies occurred after September 30.
Non-GAAP adjusted net loss was $66.8 million versus $37.2 million. Operating expenses were $77.3 million, compared with $42.8 million, and net cash used in operations was $66.2 million versus $44.8 million. Celcuity paid Pfizer $50.0 million upon FDA approval under its license agreement. Cash, cash equivalents and short-term investments totaled $642.7 million at September 30, and Celcuity expects its current balances to finance operations through 2029. It submitted an sNDA based on VIKTORIA-1 mutant-cohort data; enrollment continues in the VIKTORIA-2 first-line trial.
Celcuity Inc. director Leo Furcht exercised 250 fully vested stock options on October 7, 2026, at an exercise price of $7.60 per share, acquiring 250 shares of common stock. After the exercise, he directly held 12,780 common shares. The option-related entry reports a resulting balance of 0 options.
Celcuity Inc. director David W. Gryska received an award of 893 restricted stock units on October 1, 2026. The units will vest upon the earlier of Celcuity’s 2027 annual meeting of stockholders or April 30, 2027. The reported post-transaction total was 893 shares.
Celcuity Inc. appointed David W. Gryska as a director effective October 1, 2026, increasing its board from eight members to nine. The board also appointed him to its Audit and Compensation Committees and determined that he qualifies as an independent director under Nasdaq listing standards and SEC rules. His term extends through the 2027 Annual Meeting and election of his successor, or his earlier death, resignation or removal.
Celcuity’s non-employee director compensation program provides an annual cash retainer of $70,000, payable quarterly, and an annual equity award with a fair market value of $100,000, payable in restricted stock units, stock options or a combination at the director’s election. Celcuity granted Gryska a prorated annual award of 893 restricted stock units under its 2026 Stock Incentive Plan; all shares vest upon the earlier of the 2027 Annual Meeting or April 30, 2027. The company’s announcement says Gryska has over 35 years of strategic and financial leadership experience in the life sciences industry.
Celcuity Inc. (CELC) announced that REVTORPYK (gedatolisib) became commercially available in the United States on September 30, 2026, for eligible adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a detected PIK3CA mutation after progression following at least one line of endocrine therapy in the metastatic setting. The FDA approved REVTORPYK on July 14, 2026, with fulvestrant, with or without palbociclib.
In the PIK3CA wild-type cohort of Phase 3 VIKTORIA-1, the triplet and doublet reduced the risk of disease progression or death by 76% and 67%, respectively, compared with fulvestrant. Stomatitis occurred in 72% of patients receiving the triplet, including Grade 3 events in 22%, and in 58% receiving the doublet, including Grade 3 events in 12%. Celcuity submitted a supplemental New Drug Application in August for the PIK3CA-mutated group; if approved, physicians could prescribe REVTORPYK regardless of tumor PIK3CA status. The company also launched patient services for insurance, reimbursement and financial assistance.
Celcuity Inc. (CELC) reported the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for REVTORPYK (gedatolisib) to treat adults with HR+/HER2-, PIK3CA-mutated locally advanced or metastatic breast cancer after at least one prior endocrine therapy. The sNDA is supported by the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 trial, where the REVTORPYK-triplet (with fulvestrant and palbociclib) reduced risk of disease progression or death by 50% versus alpelisib plus fulvestrant and achieved median progression-free survival of 11.1 months versus 5.6 months. The REVTORPYK-doublet (with fulvestrant) reduced risk by 49% and achieved median progression-free survival of 11.3 months versus 5.6 months, with robust objective response rates and durable responses. REVTORPYK is already FDA-approved for HR+/HER2- advanced breast cancer without a PIK3CA mutation, and this filing seeks to expand its labeled population.